{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:50:49Z","timestamp":1794084649747,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS114"],"award-info":[{"award-number":["YDZJ202201ZYTS114"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Scientific Research Foundation of The First Hospital of Jilin University","award":["JDYY13202208"],"award-info":[{"award-number":["JDYY13202208"]}],"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32371429"],"award-info":[{"award-number":["32371429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03894-x","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:55:59Z","timestamp":1764644159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Shiyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"4","key":"3894_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"3894_CR2","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Sem Cancer Biol. 2015;35:S185\u201398.","journal-title":"Sem Cancer Biol"},{"issue":"8","key":"3894_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00109-024-02463-3","volume":"102","author":"MA Ortega","year":"2024","unstructured":"Ortega MA, Boaru DL, De Leon-Oliva D, Fraile-Martinez O, Garc\u00eda-Montero C, Rios L, et al. PD-1\/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications. J Mol Med. 2024;102(8):987\u20131000.","journal-title":"J Mol Med"},{"issue":"1","key":"3894_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12951-024-02727-7","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen Y, Ji D-K, Huang Y, Huang W, Dong X, et al. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer. J Nanobiotechnol. 2024;22(1):461.","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"3894_CR5","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha J-H. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32(12):4235\u201355.","journal-title":"Mol Ther"},{"issue":"3","key":"3894_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174\u201389.","journal-title":"Nat Rev Cancer"},{"issue":"30","key":"3894_CR7","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1038\/s41388-018-0252-x","volume":"37","author":"S Wang","year":"2018","unstructured":"Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y, et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin \u03b24\/SNAI1\/SIRT3 signaling pathway. Oncogene. 2018;37(30):4164\u201380.","journal-title":"Oncogene"},{"issue":"6","key":"3894_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 2019;74(6):1215\u2013e264.","journal-title":"Mol Cell"},{"issue":"12","key":"3894_CR9","doi-asserted-by":"publisher","first-page":"e01039","DOI":"10.1016\/j.heliyon.2018.e01039","volume":"4","author":"X Wu","year":"2018","unstructured":"Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, et al. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018;4(12):e01039\u2013e.","journal-title":"Heliyon"},{"issue":"1","key":"3894_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3894_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"},{"key":"3894_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114904","volume":"199","author":"M Shi","year":"2023","unstructured":"Shi M, McHugh KJ. Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. Adv Drug Deliv Rev. 2023;199:114904.","journal-title":"Adv Drug Deliv Rev"},{"key":"3894_CR13","doi-asserted-by":"publisher","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975","DOI":"10.3389\/fimmu.2023.1167975"},{"issue":"10","key":"3894_CR14","doi-asserted-by":"publisher","first-page":"e26333","DOI":"10.4161\/onci.26333","volume":"2","author":"B Baldo","year":"2013","unstructured":"Baldo B. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology. 2013;2(10):e26333.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3894_CR15","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","volume":"11","author":"G Lu","year":"2020","unstructured":"Lu G, Nishio N, van den Berg NS, Martin BA, Fakurnejad S, van Keulen S, et al. Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates. Nat Commun. 2020;11(1):5667.","journal-title":"Nat Commun"},{"key":"3894_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115984","author":"D Liu","year":"2024","unstructured":"Liu D, Wen C, Chen L, Ye M, Liu H, Sun X, et al. The emerging roles of PD-L1 subcellular localization in tumor immune evasion. Biochem Pharmacol. 2024;220:115984. https:\/\/doi.org\/10.1016\/j.bcp.2023.115984.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"3894_CR17","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18(9):2162\u201374.","journal-title":"Cell Rep"},{"issue":"11","key":"3894_CR18","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16(11):2829\u201337.","journal-title":"Cell Rep"},{"key":"3894_CR19","doi-asserted-by":"publisher","first-page":"123387","DOI":"10.1016\/j.biomaterials.2025.123387","volume":"322","author":"Z Li","year":"2025","unstructured":"Li Z, Ren G, Wang X, Li X, Ding L, Zhu J, et al. Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy. Biomaterials. 2025;322:123387.","journal-title":"Biomaterials"},{"key":"3894_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.718","author":"J Wang","year":"2022","unstructured":"Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, et al. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin Transl Med. 2022;12(1):e718. https:\/\/doi.org\/10.1002\/ctm2.718.","journal-title":"Clin Transl Med"},{"key":"3894_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216318","author":"Q Lin","year":"2023","unstructured":"Lin Q, Wang X, Hu Y. The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells. Cancer Lett. 2023;569:216318. https:\/\/doi.org\/10.1016\/j.canlet.2023.216318.","journal-title":"Cancer Lett"},{"key":"3894_CR22","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.2147\/IJN.S459710","volume":"19","author":"YJ Wang","year":"2024","unstructured":"Wang YJ, Deng TT, Liu X, Fang XY, Mo YP, Xie N, et al. Smart nanoplatforms responding to the tumor microenvironment for precise drug delivery in cancer therapy. Int J Nanomed. 2024;19:6253\u201377.","journal-title":"Int J Nanomed"},{"issue":"4","key":"3894_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17(4):251\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3894_CR24","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.1021\/acs.nanolett.7b03531","volume":"17","author":"J Li","year":"2017","unstructured":"Li J, Li Y, Wang Y, Ke W, Chen W, Wang W, et al. Polymer prodrug-based nanoreactors activated by tumor acidity for orchestrated oxidation\/chemotherapy. Nano Lett. 2017;17(11):6983\u201390.","journal-title":"Nano Lett"},{"key":"3894_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2016.01.029","volume":"225","author":"J Li","year":"2016","unstructured":"Li J, Ke W, Wang L, Huang M, Yin W, Zhang P, et al. Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemotherapy. J Control Release. 2016;225:64\u201374.","journal-title":"J Control Release"},{"issue":"18","key":"3894_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101454","volume":"8","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Cui H, Zhang R, Zhang H, Huang W. Nanoparticulation of prodrug into medicines for cancer therapy. Adv Sci. 2021;8(18):2101454.","journal-title":"Adv Sci"},{"issue":"5","key":"3894_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","volume":"23","author":"Z Fralish","year":"2024","unstructured":"Fralish Z, Chen A, Khan S, Zhou P, Reker D. The landscape of small-molecule prodrugs. Nat Rev Drug Discov. 2024;23(5):365\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"51","key":"3894_CR28","doi-asserted-by":"publisher","first-page":"23198","DOI":"10.1002\/anie.202008732","volume":"59","author":"S Zhou","year":"2020","unstructured":"Zhou S, Hu X, Xia R, Liu S, Pei Q, Chen G, et al. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment. Angew Chem Int Ed. 2020;59(51):23198\u2013205.","journal-title":"Angew Chem Int Ed"},{"issue":"50","key":"3894_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq2216","volume":"8","author":"TC Do","year":"2022","unstructured":"Do TC, Lau JW, Sun C, Liu S, Kha KT, Lim ST, et al. Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras. Sci Adv. 2022;8(50):eabq2216.","journal-title":"Sci Adv"},{"key":"3894_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2025.01.008","volume":"379","author":"B Zhang","year":"2025","unstructured":"Zhang B, Qin C, Wang X, Shen C, Li S, Liu T, et al. Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation. J Control Release. 2025;379:221\u201335.","journal-title":"J Control Release"},{"issue":"1","key":"3894_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12951-023-02062-3","volume":"21","author":"D Li","year":"2023","unstructured":"Li D, Ren T, Ge Y, Wang X, Sun G, Zhang N, et al. A multi-functional hypoxia\/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of Chloroethylnitrosouea. J Nanobiotechnol. 2023;21(1):291.","journal-title":"J Nanobiotechnol"},{"issue":"30","key":"3894_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202402322","volume":"36","author":"K Wang","year":"2024","unstructured":"Wang K, Jiang M, Li T, Liu Y, Zong Q, Xu Q, et al. A synergistic chemoimmunotherapy system leveraging PD-L1 blocking and bioorthogonal prodrug activation. Adv Mater. 2024;36(30):2402322.","journal-title":"Adv Mater"},{"issue":"6","key":"3894_CR33","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, et al. Chemotherapy induces enrichment of CD47(+)\/CD73(+)\/PDL1(+) immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018;115(6):E1239-e48.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3894_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.70015","volume":"11","author":"X Kang","year":"2025","unstructured":"Kang X, Zhang L, Liu S, Wang F, Liu H, Zhou F, et al. Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer. J Pathol Clin Res. 2025;11(1):e70015.","journal-title":"J Pathol Clin Res"},{"key":"3894_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.652266","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, et al. Hypoxia in breast cancer\u2014scientific translation to therapeutic and diagnostic clinical applications. Front Oncol. 2021;11:652266. https:\/\/doi.org\/10.3389\/fonc.2021.652266.","journal-title":"Front Oncol"},{"issue":"6","key":"3894_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393\u2013410.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3894_CR37","doi-asserted-by":"publisher","first-page":"e202102895","DOI":"10.1002\/slct.202102895","volume":"7","author":"S Das","year":"2022","unstructured":"Das S, Indurthi HK, Asati P, Sharma DK. Small molecule fluorescent probes for sensing and bioimaging of nitroreductase. ChemistrySelect. 2022;7(1):e202102895.","journal-title":"ChemistrySelect"},{"key":"3894_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2022.106314","volume":"153","author":"Q Wu","year":"2022","unstructured":"Wu Q, Xu Y, Li X, Liu H, You T, Cai T, et al. YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1\/PD-L1 pathway in breast cancer. Int J Biochem Cell Biol. 2022;153:106314.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"3894_CR39","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms24076420","volume":"24","author":"D Alkaabi","year":"2023","unstructured":"Alkaabi D, Arafat K, Sulaiman S, Al-Azawi AM, Attoub S. PD-1 independent role of PD-L1 in Triple-Negative breast cancer progression. Int J Mol Sci. 2023;24(7):6420.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3894_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002746","volume":"8","author":"F Sun","year":"2021","unstructured":"Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, et al. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer. Adv Sci. 2021;8(4):2002746.","journal-title":"Adv Sci"},{"issue":"4","key":"3894_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3894_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3894_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12951-025-03485-w","volume":"23","author":"H Liao","year":"2025","unstructured":"Liao H, Chen M, Liao Z, Luo Y, Chen S, Tan W, et al. Sonodynamic therapy-boosted biomimetic nanoplatform targets ferroptosis and CD47 as vulnerabilities for cancer immunotherapy. J Nanobiotechnol. 2025;23(1):432.","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"3894_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"3894_CR45","doi-asserted-by":"publisher","unstructured":"Huang KC-Y, Chiang S-F, Chen WT-L, Chen T-W, Hu C-H, Yang P-C et al. Decitabine augments Chemotherapy-Induced PD-L1 upregulation for PD-L1 Blockade in colorectal cancer. Cancers. 2020;12(2):462. https:\/\/doi.org\/10.3390\/cancers12020462","DOI":"10.3390\/cancers12020462"},{"issue":"23","key":"3894_CR46","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75(23):5034\u201345.","journal-title":"Cancer Res"},{"issue":"6","key":"3894_CR47","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","volume":"11","author":"HY Ng","year":"2018","unstructured":"Ng HY, Li J, Tao L, Lam AK-Y, Chan KW, Ko JMY, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation. Translational Oncol. 2018;11(6):1323\u201333.","journal-title":"Translational Oncol"},{"issue":"4","key":"3894_CR48","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3892\/or.2017.5894","volume":"38","author":"S Funaki","year":"2017","unstructured":"Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M, Okumura M. Chemotherapy enhances programmed cell death 1\/ligand 1 expression via TGF-\u03b2 induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep. 2017;38(4):2277\u201384.","journal-title":"Oncol Rep"},{"issue":"1","key":"3894_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12951-025-03521-9","volume":"23","author":"L Gong","year":"2025","unstructured":"Gong L, Liu Y, Feng J, Xiao C, Liu C, Chen B, et al. An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2\u2009+\u2009overload triggered pyroptosis. J Nanobiotechnol. 2025;23(1):447.","journal-title":"J Nanobiotechnol"},{"key":"3894_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","volume":"83","author":"H Fatma","year":"2022","unstructured":"Fatma H, Maurya SK, Siddique HR. Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol. 2022;83:166\u201376.","journal-title":"Semin Cancer Biol"},{"issue":"24","key":"3894_CR51","doi-asserted-by":"publisher","first-page":"24972","DOI":"10.1021\/acsnano.3c07183","volume":"17","author":"C Guo","year":"2023","unstructured":"Guo C, Wu M, Guo Z, Zhang R, Wang Z, Peng X, et al. Hypoxia-responsive golgi-targeted prodrug assembled with anthracycline for improved antitumor and antimetastasis efficacy. ACS Nano. 2023;17(24):24972\u201387.","journal-title":"ACS Nano"},{"issue":"23","key":"3894_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202314132","volume":"36","author":"S Zhang","year":"2024","unstructured":"Zhang S, Lai Y, Pan J, Saeed M, Li S, Zhou H, et al. PROTAC prodrug-integrated nanosensitizer for potentiating radiation therapy of cancer. Adv Mater. 2024;36(23):2314132.","journal-title":"Adv Mater"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03894-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03894-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03894-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:02:39Z","timestamp":1767715359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03894-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3894"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03894-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental operations were executed in accordance with the guidelines established by the Institutional Animal Care and Use Committee of College of Basic Medical Sciences, Jilin University (Ethics approval No. 2025316).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}